Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the incidence, reversibility, and impact of chemotherapy-induced alopecia and concludes that scalp cooling is the most effective prevention method in most cases, though some questions remain.

This review discusses the causes, clinical presentation, and management of anagen effluvium, emphasizing its psychological impact and the need for empathy and practical support, but reports no new results.

This study found that irreversible and severe alopecia can occur following docetaxel or paclitaxel chemotherapy in breast cancer patients.

This review discusses interventions for chemotherapy-induced hair loss and reports no new clinical results; scalp cooling and nutritional support are considered potential strategies but not yet substantiated.

This study observed various patterns of permanent alopecia in breast cancer patients treated with taxanes and adjuvant hormonal chemotherapy, hypothesizing disruptions in hair follicle cycles due to chemoinflammatory and hormonal factors.

In this NIH study, female donor to male recipient sex mismatch was significantly associated with the development of vitiligo and/or alopecia areata in patients with chronic graft-vs-host disease.

This review discusses the clinical characteristics of alopecia in cancer patients, highlighting its potential role as an associated finding or diagnostic clue, but reports no new clinical results.

This case report describes a 26-year-old female with linear morphea and unique alopecia characterized by atrophic follicular remnants, resembling telogen follicles but indicating permanent alopecia, unlike typical findings in morphea-related alopecia.

This article reviews drug-induced hair and nail disorders and discusses their clinical recognition, underlying mechanisms, and potential treatment strategies, without presenting new research findings.

This narrative review provides an overview of the persistent dermatological side effects experienced by cancer survivors due to treatments, highlighting their impact on quality of life and the need for structured dermatological care during survivorship.

This report presents a case where a 17-year-old male developed severe unilateral alopecia following radiotherapy for pediatric glioblastoma multiforme, which did not respond to minoxidil or platelet-rich plasma treatments.

In this study, researchers examined common chemotherapy side effects among 100 Pakistani cancer patients and explored the potential side effect reduction through hunger-based differential chemotherapy. They found widespread adverse reactions, with only 18% willing to fast for over 24 hours.

This review discusses the impact of chemotherapy-induced alopecia on cancer patients, the current use of scalp cooling for prevention, and potential future treatments, but presents no new clinical results.

This study reviews drug-induced hair changes, noting that hair loss often reverses after stopping the drug, but permanent alopecia cases post-chemotherapy are rising.

Treatments for acute leukaemia lead to high remission rates, but relapses occur, requiring ongoing advancements in care.

This review examines dermatological side effects of taxane chemotherapy reported in past studies and highlights the necessity for identifying and managing these conditions to maintain cancer patients' quality of life; it presents no new clinical results.

This article reviews the cutaneous reactions and characteristic skin changes associated with chemotherapy, radiation therapy, and new targeted cancer treatments, reporting no new clinical results.

This study reports no known changes in hair pigmentation associated with brentuximab vedotin, despite its various other documented adverse effects.

This case report documents a 57-year-old man with nephrotic syndrome linked to recurrent chronic graft-versus-host disease and lupus-like symptoms, with improvement after cyclosporin and steroids; however, he died later from leukemia relapse.

In this retrospective cohort study, 87.1% of pediatric patients with chemotherapy-induced alopecia experienced clinical improvement after treatment with minoxidil or combination therapy with CYP, with the combination therapy showing greater hair thickness and minimal adverse effects.

This case report describes a patient with permanent chemotherapy-induced alopecia who experienced full hair regrowth after treatment with low-dose oral minoxidil.

This review highlights the challenges and management strategies associated with persistent chemotherapy-induced alopecia, detailing the psychosocial impacts, follicular pathobiology, and available treatments such as scalp cooling and minoxidil, ultimately proposing a clinical algorithm to transform it into a preventable and manageable condition.

This study reports that persistent chemotherapy-induced alopecia in breast cancer patients frequently resembles androgenetic alopecia, and treatment with minoxidil, alone or with antiandrogens, improved hair density in many cases.

In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.

Chemotherapy patients don't all lose their hair due to factors like hair growth rates, age, genetics, and the type of drugs used.

This study reports that scalp cooling therapies and minoxidil may promote hair regrowth in patients experiencing persistent chemotherapy-induced alopecia, with trichoscopy aiding in treatment assessment.

This report describes a case where a woman developed permanent alopecia after chemotherapy with taxanes for breast cancer, and she showed favorable response to 6 months of minoxidil topical treatment.

This report documents a case where a man survived sub-acute toxicity from an overdose of the anticancer drug UFT due to effective treatment with antibiotics and granulocyte colony-stimulating factor.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.

This study found that combining hair transplantation with platelet-rich plasma led to significantly better outcomes, such as reduced hair loss area and increased hair regeneration, compared to hair transplantation alone in patients with androgenic alopecia.